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ABSTRACT 
In 1990, there was essentially one treatment regimen in use for 
visceral leishmaniasis (kala-azar) around the world: 20 to 28 
days of daily injections of pentavalent antimony (Sb). During 
the past 10 years, however, new agents have been tested 
alone or in combination, in more than 50 studies carried out 
worldwide. This renewed clinical effort was spurred by a vari- 
ety of factors, including the emergence of large-scale Sb unre- 
sponsiveness in India, where up to one-half of the world’s cases 
of kala-azar now are found. As this new decade opens, the 
success of this clinical research effort is tangible: three addi- 
tional, highly effective parenteral regimens now are available 
(amphotericin B, lipid formulations of amphotericin B, amino- 
sidine), and an active oral agent, a long sought after objective 
in kala-azar, has been identified (miltefosine). This report reviews 
the evolution of treatment of visceral leishmaniasis, considers 
the interaction of the immune response and chemotherapy, 
highlights therapeutic successes and failures, examines advan- 
tages and disadvantages of current treatments, and looks at 
future therapeutic approaches to the management of this dis- 
seminated intracellular protozoa1 infection. 
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Visceral leishmaniasis (kala-azar), a disseminated intra- 
cellular protozoa1 infection transmitted by sandflies, 
occurs primarily in rural areas in developing countries. 
In infected children and adults who progress to a symp- 
tomatic state, typical findings include fever, weight loss, 
hepatosplenomegaly, and pancytopenia. Traditional mea- 
sures to prevent infection have been either unsuccessful 
(vector control) or unrealistic (reservoir control) or still 
are unavailable (vaccine). 
In 1990, at the outset of the decade just passed, there 
was only one recommended approach to initial treatment 
of kala-azar around the world: 20 to 28 daily injections of 
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one of various forms of pentavalent antimony (Sb), prepa- 
rations in use for over 50 years and, until recently, neither 
improved upon nor considered a priority to replace. In 
2000 and despite well-recognized drawbacks, Sb contin- 
ues (at least for the present) to be the drug of choice for 
treatment of kala-azar in all regions of the world except 
India. Pentavalent antimony has maintained its position 
primarily because it is affordable and surely time-tested 
and, over the years, no other clearly advantageous alter- 
native treatment has emerged. This latter situation, how- 
ever, has changed (Figure 1). 
Since the mid-199Os, renewed experimental and clin- 
ical efforts aimed at optimizing treatment of visceral 
infection have successfully fused to rapidly yield a vari- 
ety of tangible therapeutic dividends and new treatment 
options. These efforts have led to rediscovery of drugs 
previously considered second-line; thorough study of 
novel, highly active agents that have made short-course 
treatment possible; testing of drug combinations, includ- 
ing immunochemotherapy; new focus on developing 
more cost-effective treatment; and in just the past year, 
identification of what appears to be the first active oral 
agent. 
Sb” Aminosidine 
Amphotericin B Sbv + IFN-7 or 
Aminosidine 
Lipid Forms of 
Amphotericin B* Miltefosine 
Figure 1. Progress made since 1990 in developing new treatment 
options in kala-azar. Sb” = pentavalent antimony; IFN--y = intetferon- 
gamma. *Lipid formulations of amphotericin B: amphotericin B cho- 
lesterol dispersion (Amphotec), amphotericin B lipid complex (Abelcet), 
liposomal amphotericin B (AmBisome), and amphotericin B-fat emulsion. 
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At the same time, in the 1990% new obstacles to the 
management of kala-azar emerged, mirroring treatment 
experiences encountered in other worldwide infectious 
diseases.’ The development of high-level resistance to 
conventional Sb therapy in the region where infection 
most frequently occurs (India); intersection with human 
immunodeficiency virus (HIV), with a predictable increase 
in treatment failures; and the prohibitive cost of the most 
recently introduced new class of drugs are three currently 
prominent therapeutic obstacles in the search for opti- 
mal treatment of kala-azar. Other obstacles in endemic 
areas, including limited access to timely medical care and 
proper drug treatment, and the likely adverse effects of fac- 
tors such as poor nutrition are not new. 
Although this report focuses on therapeutic 
advances, it also summarizes the evolution of the treat- 
ment of kala-azar; reviews selected features, including 
immunoclinical factors that may influence the need for 
or response to therapy; highlights existing hindrances to 
optimal drug management; and suggests future 
approaches. Other recently published articles have 
reviewed current clinical and epidemiologic information 
about all forms of leishmaniasis and have considered 
antileishmanial treatment in a general fashion or from 
other perspectives. z-6 These and other pertinent reports 
also provide specific treatment-related details not neces- 
sarily covered in depth here.’ 
GEOGRAPHIC DISTRIBUTION 
Depopulating epidemics of what was probably kala-azar 
(Hindi for “black sickness” or “black fever”) swept through 
northeastern India as early as the 1850s and perhaps 
before.8 In 1903, Leishman reported seeing the protozoan 
ultimately proven responsible for this infection in post- 
mortem splenic smears from a British soldier who had 
been stationed outside of Calcutta, at Dum-dum.” This 
young rifleman had been invalided home in 1900 and 
died 7 months later with persistent fever, marked cachexia, 
“grave” anemia, and massive splenomegaly. Ieishman’s arti- 
cle triggered Donovan to report similar autopsy findings, 
from Madras, in three native Indians; Donovan also found 
the parasite in smears of a splenic aspirate performed 
antemortem.‘” By 1904, the name given to this pathogen, 
Leishmania donovani, was in wide use.8 
Currently, kala-azar is reported in both children and 
adults in more than 60 countries, and crude estimates 
suggest as many as 500,000 new cases worldwide per 
year. Ninety percent of cases are thought to arise in just 
four countries (India, Sudan, Bangladesh, and Nepal)“; 
one-half of these may occur in Northeast India alone.1iJ2 
Whereas kala-azar is endemic in Brazil, Kenya, Ethiopa, 
southern Europe along the Mediterranean basin, and 
China, the decades-old epidemics in rural India and in 
displaced refugees in Sudan provide the principal sources 
of new cases. Although strains ordinarily associated with 
cutaneous infection, such as Leishmania tropica, occa- 
sionally produce visceral disease,13,‘* kala-azar most often 
is caused by L. donovani (India, Asia, Africa), Leishmania 
infantum (the Mediterranean region), and Leishmania 
chagasi (South America). 
In addition to differing etiologic strains, the effect of 
geography on kala-azar also is evident in the predomi- 
nantly affected age groups and the magnitude of visceral 
parasite burden, factors that probably alter the response 
to treatment. Fifty years ago, for example, the response to 
therapy in visceral infection in Africa and Asia was con- 
sidered worst in East Africa and Sudan, fair in China, and 
best in India, despite infection being caused in each of 
these regions by the same species, L. donovani.‘5,‘” Two 
factors that may have explained this “best response” opin- 
ion about kala-azar in India were (and likely still are) the 
older age groups of affected patients and the presence of 
considerably lower loads of tissue parasites, as indicated 
by microscopic estimates using splenic aspirate smears.‘7.‘8 
Results from the only multicentered trial in kala-azar 
carried out on more than one continent suggest that 
regional differences in the response to treatment (unre- 
lated to parasite drug resistance) still exist.‘8 In that inter- 
national trial, the total dose of the agent tested (liposomal 
amphotericin B) necessary to produce high-level, long- 
term cure (> 90%) ranged from 6 (India) to 10 (Kenya) 
to 20 mg/kg or more (Brazil).‘* Principal differences 
among the three regional groups of patients included the 
responsible etiologic strain (L. donovani in India and 
Kenya, L. chagasi in Brazil), appreciably higher splenic 
parasite density scores in Brazilian and Kenyan subjects, 
and wide variation in the ages of treated subjects (mean 
ages: Brazil, 9 y, Kenya, 14 y, India, 25 y).18 Such age dif- 
ferences were not unexpected since kala-azar in India 
and Kenya affects both adults and children, whereas in 
Brazil, it is largely a disease of young children.’ Mediter- 
ranean kala-azar (L. infantum) also is primarily a disease 
of children; in this region, the recommended total dose 
of liposomal amphotericin B also is high (~18 
mg/kg).7.*9~20 In young children, a disproportionately larger 
amount of parasitized reticuloendothelial tissue relative 
to body weight may account for the need for higher doses 
of drug given on a milligram per kilogram basis.‘.18 
CLINICAL SPECTRUM, IMMUNE 
RESPONSE, AND NEED FOR TREATMENT 
Irrespective of geography, fully developed kala-azar usu- 
ally is expressed clinically as a subacute or chronic febrile 
illness accompanied by constitutional complaints, weight 
loss, some liver enlargement, prominent to striking 
splenomegaly, and pancytopenia.‘z3,5 In some regions, diar- 
rhea and lymphadenopathy also are common. In such 
symptomatic patients, intracellular amastigotes readily are 
identified within macrophages of the bone marrow, liver, 
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or spleen (Figure 2) the principal target organs in this 
infection. All patients with this fully established form of 
the disease clearly require specific treatment. 
In contrast, recent observations from a number of, but 
not all endemic areas indicate that infection with vis- 
ceralizing Leishmania strains most often does not 
progress to the full clinical syndrome of kala-azar.*i 
Instead, infection remains subclinical in as many as 85% 
of otherwise healthy individuals, or produces compara- 
tively mild oligosymptomatic disease that may also spon- 
taneously reso1ve.3*13,22-26 Thus, more often than not, 
infection caused by visceralizing strains is asymptomatic 
and requires no treatment. 
Successful Immune Response 
One likely determinant of the preceding divergent clini- 
cal outcomes is whether an effective cell-mediated 
immune response develops promptly and successfully 
evolves to full, unopposed expression, therefore necessi- 
tating no treatment.*’ Although specific antileishmanial 
IgG antibody is almost invariably present in infected, oth- 
erwise healthy patients, this humoral immune response 
induces neither initial nor long-lasting protective effects. 
(In HIV-associated kala-azar, the majority of co-infected 
patients do not develop antileishmanial IgG antibody.‘.’ 
Complex but well-characterized experimentally, the 
key cell-mediated immune response in visceral infection 
is T cell (largely CD4, T helper 1 [Thll-type, cell)depen- 
dent and multi-cytokinedriven. This response culminates 
in granuloma assembly, macrophage activation with killing 
of intracellular amastigotes, induction of life-long quies- 
cence of residual, surviving tissue parasites, and resistance 
to rechallenge.” In human infection, for example, spe- 
cific T cell reactivity to leishmanial antigen in vitro, includ- 
ing the capacity to secrete the Thl cell-derived, 
macrophage-activating cytokine, interferon-y (JFN-y), skin 
Figure 2. Giemsa-stained splenic aspirate smear from an Indian 
patient with kala-azar showing splenic macrophage (center) heavily 
parasitized with replicating intracellular L. donovani amastigotes (Orig- 
inal magnification, x500). Smear prepared and provided by Dr. Shyam 
Sundar, Banaras Hindu University, Varanasi, India. 
test responses (delayed-type hypersensitivity), and the 
presence of granulomas in involved tissue all are associ- 
ated with the subclinical state.24,26~28-“2 
In addition to inducing acquired resistance in exper- 
imental visceral infection and apparently being able to 
spontaneously abort progression to fully established clin- 
ical kala-azar, this same T cell-dependent mechanism also 
may play an important facilitating role in in vivo respon- 
siveness to Sb therapy.33 Largely IFN-y-mediated,34 the 
diminished activity or absence of such a mechanism may, 
at least in part, bear on the problem of frequent Sb treat- 
ment failures in acquired immunodeficiency syndrome 
(AIDS)-related visceral leishmaniasis.35x36 
Unsuccessful Immune Response 
In some instances of progressive visceral infection, thus 
far also best defined in experimental models, the pre- 
ceding Thl cell-associated responses appear simply to 
fail to matures’; hyporesponsiveness to interleukin 12 (IL- 
12) a critical initiating cytokine, may be involved.38 How- 
ever, it is clear that the pro-host defense Thl cell 
mechanism also can be actively impeded or its effects 
altogether extinguished by a simultaneously provoked, 
Th2 cell-associated CD4 cell response.39-43 In such a set- 
ting, suppressive Th2 cell cytokines (IL-4, IL-IO, IL-13, and 
probably others) can redirect the CD4 cell response, 
inhibit pro-inflammatory cytokine secretion, or deacti- 
vate macrophages, thus, initially promoting and then per- 
petuating intracellular infection.39-43 An additional 
cytokine, transforming growth factor-j3 (TGF-P), also may 
inhibit macrophage activation.“4,45 
Therefore, by virtue of inducing Thl cell or 
macrophage deactivation, a prominent or persistent Th2 
cell-type response may: (1) limit effector cell function 
and essentially neutralize the immunologic arm of the 
host response to treatment, (2) reduce initial treatment 
efficacy by imposing a considerably higher parasite tissue 
burden against which a drug is required to act, and 
(3) potentially foster either rapid recurrence or remote 
relapse of infection after apparently effective therapy.46x4’ 
Manipulating Immune Mechanisms 
to Enhance Response to Treatment 
Although the macrophage-activator, IFN-y, is present in 
the circulation as protein or as mRNA in parasitized tis- 
sues of patients with fully established kala-azar,41,42~47-49 
these same infected sites also contain IL-10 or IL-4, fac- 
tors capable of efficiently offsetting antileishmanial host 
defense.41,42,47-50 Thus, at least theoretically, IL-10 and IL-4 
(and perhaps TGF-P) by themselves represent potential 
targets for future treatment, that is, inhibition of their 
effects by adjunctive therapy using anti-cytokine or anti- 
cytokine receptor monoclonal antibody. Such treatment 
would be designed to be combined with and presumably 
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augment the efficacy of a conventional antileishmanial 
agent.“” 
Rather than intervening immunologically by inhibit- 
ing a suppressive cytokine or mechanism, an alternative, 
positive approach to enhance the response to antileish- 
manial chemotherapy consists of inducing macrophage 
or T cell activation.27~5’-54 Such intervention also might 
act in part to simultaneously inhibit the Th2 
response.““a5i,5” For example, five cytokines, several of 
which are members of the Thl cell family, have been 
identified experimentally as macrophage- or T cell-acti- 
vating components of the successful antileishmanial 
mechanism.27 In various other human disease settings, all 
five either have been tested in phase I trials (tumor necro- 
sis factor-a [TNF-a] , IL-l 2) or are already in clinical use 
for other indications (IL-2, IFN-y, granulocyte-macrophage 
colony-stimulating factor [GM-CSF]). Two of these five 
cytokines, IFN-), and GM-C@ have been tested in patients 
with kala-azar either alone or in combination with Sb,5’-ti 
and IL-12 has been used successfully in experimental 
infection in conjunction with Sb.52.65 
Thus, although currently theoretic, it is not difficult 
to appreciate the appeal of rational, sequential immuno- 
chemotherapy in kala-azar. Such a regimen might be 
designed to first neutralize the effect of a Th2 response, 
then enhance T cell reactivity or induce effector cell acti- 
vation by injecting a pro-host defense cytokine, such as 
IL-12 or IFN-?/, and follow this treatment with antileish- 
mania1 chemotherapy. This approach would require a 
number of steps, including development of an anti-Th2 
cell agent and a relevant animal model for in vivo testing, 
before the practical logistics of such a sophisticated clin- 
ical study and funding to support it could even be con- 
sidered. Sufficient funds would not likely be found in a 
typical endemic region. 
EVOLUTION OF CHEMOTHERAPY TO 1990 
Antimonials 
The trivalent antimonial, tartar emetic, already tested in 
cutaneous leishmaniasis, was used as the first pharmaco- 
logic treatment for kala-azar in 1915 in Italy and India.” 
In the 1920s to 193Os, different forms of pentavalent Sb, 
including urea stibamine, were introduced and decreased 
the length of parenteral treatment from 3 to 4 months to 
several weeks. Organic pentavalent Sb was further mod- 
ified in the 1940s to sodium antimony gluconate,‘5x’6 and 
over the next three decades, two such preparations, 
sodium stibogluconate and meglumine antimoniate, essen- 
tially replaced all other treatments for kala-azar. Initial Sb 
regimens in some regions were as brief as 6 to 10 days, 
and daily doses were as low as 9 mg/kg.“@’ Over the 
years, however, and in the face of slowly developing clin- 
ical resistance in the 1970s to 198Os, both the daily dose 
of Sb and the duration of treatment for kala-azar were 
increased, to maintain satisfactory levels of efficacy (e.g., 
~90% long-term cures). Children with kala-azar appeared 
to require higher doses of Sb.66@ In 1990, the World 
Health Organization (WHO) recommended doubling the 
daily Sb dose to 20 mg/kg (up to 850 mg/d) and contin- 
uing treatment for 20 days or longer.69 In the early 199Os, 
additional recommendations included administering drug 
for 28 to 30 days and removing the maximum daily dose 
limitation (850 mg),?” which presumably resulted in sub- 
optimal dosing for patients weighing more than 42 kg. 
Current pentavalent Sb preparations include: (1) meg- 
lumine antimoniate available as Glucantime (Specia 
Rhone-Poulenc Rarer, France and Rhodia Farma Ltd., 
Brazil) and (2) sodium stibogluconate. The latter is avail- 
able as Pentostam (Wellcome Foundation Ltd., London, 
UK), in India in three inexpensive forms as sodium anti- 
mony gluconate (Albert David, Ltd., Calcutta), Stibanate 
(Gluconate India Pvt. Ltd., Calcutta), and Abanate (Amoco 
Pharma, Muzaffarpur), and in a preparation from China 
(Shandong Xinhua Pharmaceutical Factory) now in use 
in China and Brazil.” 
Approximate costs for drug alone for a 28- to 3Oday 
treatment course at 20 mg/kg per day in an adult patient 
are: Glucantime, U.S.$lOO to $120; Pentostam, U.S.$lSO to 
$200; and sodium antimony gluconate, U.S.$15 to $16.‘9x71 
Other Agents 
Aromatic diamidines, including hydroxystilbamidine and 
pentamidine, also were introduced as treatment for kala- 
azar around 1940 and initially were widely used.15J6 
Amphotericin B deoxycholate first was tested in 1963, 
but only in three patients. 73 Neither pentamidine nor 
amphotericin B appeared to offer an obvious advantage 
over pentavalent Sb, and both carried increased cost and 
substantial toxicity and required prolonged administra- 
tion. In addition, pentamidine was not uniformly effective 
in all endemic regions,15J6 and amphotericin B essentially 
remained untested. Not surprisingly, both pentamidine and 
amphotericin B were long-considered second-line drugs. 
However, by the early 198Os, unresponsiveness to Sb 
was recognized as well-established in northeastern India 
(Bihar State),‘* the center of the Indian kala-azar epi- 
demic. Therefore, in addition to the testing of Sb in still 
higher doses and for longer periods of up to 40 days,75 
pentamidine was reexamined in Indian patients who had 
failed to respond to or had relapsed after Sb therapy. 
Despite its toxicity, pentamidine initially was viewed as 
effective and usefu13x7”; however, the efficacy of even pro- 
longed regimens (e.g., thrice-weekly injections for 5 to 9 
weeks) soon declined appreciably.“-” In this setting and 
as the cure rate induced by the now standard 28- to 
3Oday, fulldose Sb regimen (20 mg/kg/d) slipped to as 
low as 63% in Bihar,8”*81 after 1990, Indian investigators 
next turned to amphotericin B. 
During the 198Os, and into the early 199Os, various 
oral agents were tested in a limited fashion in kala-azar but 
were found to exert, at best, insufficient or inconsistent 
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effects. For example, neither allopurinol nor ketoconazole 
used alone proved to have consistent activity, and com- 
bining allopurinol with Sb did not induce additional ben- 
efits.82-87 Nevertheless, the latter regimen drew attention 
to the notion of two-drug combination therapy, which has 
been reexplored more recently using various approaches. 
BASIC RESEARCH AND 
CLINICAL INVESTIGATION 
Identifying and Testing New Approaches 
Recent work from laboratories around the world has 
enhanced the basic grasp of the biology of the Leishma- 
niu species, the mechanisms of establishing a state of per- 
sistent intracellular parasitism, and the nature of the 
cytokine-driven immunologic pathways of successful host 
defense in parasitized tissues. In parallel, applied research 
in a number of these same laboratories also has been instru- 
mental in developing relevant models in which to test new 
therapeutic approaches, in identifying parasite metabolic 
pathways potentially susceptible to rational drug-induced 
effects, and in dete rmining the experimental efficacy of a 
variety of new agents, both immunologic and pharmaco- 
~~g~~~3,27,46,51~56,65.88~107 A surprising number of these agents 
were rapidly put into clinical testing, and several currently 
form the expanding backbone of the modern, non-Sb-con- 
taining treatment regimens for kala-azar. 
This same laboratory research effort also led to 
renewed experimental and clinical appreciation of how 
antileishmanial treatment interacts with or actually 
requires the host immune response for in vivo effi- 
cacy.27*33,34,46,52,53,65,108-111 Although such interaction may 
take place initially at the time drug is given,33*“4,110 it is 
especially important after treatment, to maintain both sur- 
viving parasites in a quiescent state and the host relapse- 
free.27,46,52,108~110,112 Fii years ago, it was clear that although 
a patient with kala-azar treated with Sb, for example, 
responded and appeared cured by conventional clinical 
and parasitologic criteria, up to 20% or more of such indi- 
viduals relapsed in the subsequent 6 to 12 months.15J6,113 
The Problem of Relapse 
The same possibility of relapse currently still exists in 
any patient with kala-azar despite optimal treatment and 
what appears to be an initial complete response, includ- 
ing conversion to a negative splenic or bone marrow 
aspirate smear or culture. In leishmaniasis (and likely in 
other intracellular infections), eradication of all residual 
organisms probably is seldom achieved either pharmaco- 
logically or immunologically. 112,114,115 Thus, after treat- 
ment, even phenotypically immunocompetent individuals 
remain at risk for recurrence. As judged by experience in 
patients at particular risk for relapse (e.g., those with 
acquired T cell deficiencies associated with advanced HIV 
disease,35 organ transplantation,116 or corticosteroid treat- 
ment”‘), the key regulator of the successful relapse-free 
state after antileishmanial treatment appears to be the 
satisfactory emergence and persistence of an effective T 
cell-dependent immune response.27~46~52J12~i18 Document- 
ing conversion to a reactive leishmanin skin test, which 
may not develop for months or even a year or more after 
apparent treatment-induced cure,15J19 is one method of 
demonstrating this response; documenting the post-treat- 
ment emergence of in vitro T cell reactivity to specific 
leishmanial antigen is another. l*O 
Predicting with accuracy which drug-treated, appar- 
ently cured patients are destined to relapse is not yet 
possible. However, some evidence does suggest that the 
failure to show a substantial decrease in circulating anti- 
K39 antibody titer or the persistence of parasite DNA 
detected by polymerase chain reaction (PCR) assay in 
involved tissues (e.g., lymph node), may be markers for 
the risk of relapse after treatment.121J22 
Appropriately, therefore, concern about the poten- 
tial for relapse in kala-azar led to the incorporation of 
“apparent” and “definitive” cure evaluations into formal 
treatment trial protocols. Apparent clinical cure, assayed 
at or within 2 weeks after treatment-end (the latter time 
point to allow visible but dead or dying parasites to dis- 
appear), typically requires general clinical improvement, 
no fever, a substantial decrease in spleen size, and evi- 
dence of apparent parasitologic cure (a parasite-free 
splenic or bone marrow aspirate smear or negative cul- 
ture). Since most relapses currently are thought to occur 
within 6 months,‘22-124 long-term (definitive cure) is not 
measured until 6 or more months after treatment. Defin- 
itive cure requires a return to good health with no signs 
or symptoms suggesting relapse. In the setting of a clin- 
ical trial, especially one testing a new agent and if field 
conditions permit, a parasite-free bone marrow aspirate 
smear also can be included in a more strict definition of 
long-term cure. However, it would be unusual at the 6- 
month time point to find a positive bone marrow aspi- 
rate smear in an otherwise healthy, asymptomatic patient. 
TREATMENT IN THE EARLY 1990s: 
SHORTCOMINGS AND OBSTACLES 
Pentavalent Antimony, 
Pentamidine, and Amphotericin B 
In 1990, Sb was essentially the only drug in use in kala- 
azar. Up to this point and in view of the well-regarded effi- 
cacy of Sb, neither the necessity for 20 to 28 daily 
injections nor numerous adverse reactions (mostly mild 
to moderate, sometimes severe) was sufficient to stimu- 
late serious clinical development of new antileishmanial 
drugs.3,70J25 Low purchasing power in most endemic 
regions, a traditional obstacle to new drug development 
in virtually all tropical diseases, also served to keep the 
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new drug pipeline dry. (This difficult-to-solve problem 
currently remains a dilemma.‘) 
At this same juncture in the early 1990s pentami- 
dine and amphotericin B, seldom actually used except in 
India, continued to be ranked as second-line because of 
cost, toxicity, the need for closer monitoring for adverse 
reactions and the practical difficulty of readily obtaining 
these agents in endemic regions. In 1990, efficacy of pen- 
tamidine was beginning to flag in India,77-79 and there 
had been no clinical experience in using amphotericin B 
in kala-azar. Treatment with pentamidine or amphotericin 
B also was known to share other drawbacks with Sb, 
because each required injections or infusions as well as 
prolonged administration (alternate-day treatment usu- 
ally for 2 4 wk) with typically lengthy hospitalizations. 
Although amphotericin B was tested as initial ther- 
apy in previously untreated patients with kala-azar in 
India 80,126 it and pentamidine were employed almost 
exclusively in the early 1990s in patients who had failed 
prior Sb therapy. 77-79~‘23,127-130 In contrast to the partial 
activity of pentamidine in these patients, conventional 
amphotericin B deoxycholate proved nearly 100% effec- 
tive and has maintained this same level of efficacy to the 
present~lM27-132 
Failure of Pentavalent Antimony Treatment in India 
why clinical resistance to Sb took such a firm hold in 
northeastern India (Bihar State, where as many as 90% of 
Indian cases occur) rather than in other regions or in 
endemic areas, such as war-torn Sudan, is not entirely 
clear.11J2J33,1”4 Intermittent drug shortages necessitating 
low-dose treatment, failure to complete 4 weeks of ther- 
apy, and years of suboptimal prescribing by local physi- 
cians and rural health care workers appear to have been 
primary contributing factors and remain chronic, not eas- 
ily remedied problems. 123~135~136 True parasite resistance 
to Sb, long suspected as being present in India, has been 
formally documented in the laboratory.‘37 
By the mid-1990s and while Sb treatment failures 
remained at 5 to 10% or lower in all other parts of the 
world,2-4~133~134 7 to 64% of previously untreated patients 
in North Bihar either failed to initially respond to or 
relapsed after treatment with Sb given for 28 to 30 days 
at full dose (20 mg/kg/d).62J36J38 In some villages in this 
particular region, as many as 80% of newly diagnosed 
patients currently fail to respond to Sb.123 Since, as 
pointed out previously, close to one-half of the world’s 
cases of kala-azar may now arise in or around Bihar,“J2 
the impact of Sb resistance in this region is considerable. 
Although one recent study suggested that Sb failure 
rates also may be increasing in other areas of India,139 a 
number of these reported patients had originally acquired 
their infections in Bihar. In addition, data from neighbor- 
ing eastern Uttar Pradesh (Varanasi, 200 miles from North 
Bihar) reemphasize the focal (albeit serious) nature of 
the overall problem of Sb resistance in India. In an on- 
treatment analysis, 95 of 98 patients (97%) treated with 
Sb during 1994 to 1997 in Uttar Pradesh were cured; 
however, only 73 of 182 (40%) treated concurrently in 
Bihar by the same investigators using the same sodium 
antimony gluconate preparation and protocol (30-d reg- 
imen, 20 mg/kg/d) showed a long-term cure response.‘*O 
Based upon the preceding results as well as similar 
clinical experience,“2,136~138 there is no doubt that Sb 
should be abandoned entirely in the treatment of kala-azar 
in Bihar. In 1997, the author and colleagues stopped using 
Sb in North Bihar (Muzaffarpur).60-“2~140 Two hundred 
miles away, however, Sb still is used with confidence as 
first-line therapy in Varanasi (Uttar Pradesh). Although no 
other endemic area in the world currently shares in the 
dilemma of high-level Sb failure rates, it is worth noting 
that efficacy in Sudan, the other major epidemic region 
for kala-azar, also may be beginning to diminish.‘** 
HIV Co-infection Undermines Response 
to Antileishmanial Treatment 
Experimentally, the visceral leishmanicidal effect of Sb is 
T cell (Thl cell)-dependent and specifically requires 
endogenous IFN-y: 13,34 Thus, it was not surprising that 
the T cell (and IFN-y) -deficient state induced by 
advanced HIV infection revealed an additional short- 
coming of Sb, expressed clinically by a clear-cut increase 
in treatment failures in co-infected patients.35*36J41J42 In 
contrast, experimental antileishmanial efficacy of ampho- 
tericin B is T cell-independent,34x110 and although limited, 
early reports indicated that amphotericin B in both con- 
ventional and lipid form induced high-level initial, appar- 
ent cure effects in AIDS-associated kala-azar.35,36J43-‘4T In
T cell-depleted patients, however, once any apparently 
successful initial treatment (Sb or conventional or lipid- 
formulated amphotericin B) is discontinued, relapse is 
predictable, just as in other AIDS-related opportunistic 
infections.35,36.‘45-148 A t h ough some form of life-long, sup- 
pressive antileishmanial therapy is logical for all co- 
infected patients in whom primary treatment induces 
remission,148 currently, there is no consensus about either 
what constitutes optimal maintenance therapy or 
whether all such patients are candidates to receive this 
treatment. 
Despite under-reporting and under-testing, co-infec- 
tion with HIV is not yet common in rural areas of devel- 
oping countries such as India and Sudan, where kala-azar 
is most prevalent.‘40J49J50 However, co-infection certainly 
promises to become a critical therapeutic obstacle in 
India, Africa, and Brazil as visceral infection and HIV con- 
tinue to coincide worldwide. Southern areas of Spain, 
France, and Italy, countries with welldeveloped detec- 
tion and reporting systems for leishmaniasis and HIV 
have, to date, contributed the vast majority of the nearly 
2000 reported cases of AIDS-related kala-azar.35J49J50 In 
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otherwise healthy individuals, Mediterranean visceral 
leishmaniasis (L. infanturn) has remained responsive to 
standard Sb treatment with initial apparent cure rates of 
90 to 95% or more and few relapses.4J51J52 However, in 
HIV-infected patients in this same region, Sb is consider- 
ably less active: overall, approximately 50% show an im- 
tial apparent cure response and, if not given maintenance 
therapy, most responders are likely to relapse within 6 to 
12 months.35,‘48,‘5’.‘53 
Additional therapeutic information, recently gener- 
ated in Spain, represents the only prospective, controlled 
treatment data in HIV-related kala-azar.154 In an intention- 
to-treat analysis, these results confirmed the diminished 
response to Sb (20 mg/kg/d for 28 d; 66% initially cured) 
but also unexpectedly demonstrated an equally reduced 
response to amphotericin B (0.7 mg/kg/d for 28 d; 62% 
initial cure rate). l lo In an on-treatment analysis, appre- 
ciably higher initial cure rates were induced by both 
agents (amphotericin B, 93%; Sb, 85%). In this study,*54 
estimated probabilities of relapsing 12 months after 
initially responding to either amphotericin B or Sb (no 
secondary prophylaxis given) were 56% and 70%, respec- 
tively. This trial also highlighted the difficulties that debil- 
itated HIV-co-infected patients may have in tolerating 
antileishmanial treatment: &-treated subjects developed 
cardiotoxicity (14%) and pancreatitis (30%); 36% of those 
receiving amphotericin B experienced nephrotoxicity. 
Retrospective results from Italy also re-emphasize 
overall outcome and the magnitude of the therapeutic 
obstacle inserted by the presence of HIV into the man- 
agement of kala-azar. 151,155 In Sicily, 233 of 245 patients 
(95%) not co-infected with HIV were cured by standard 
Sb therapy; in contrast, none of 35 with AIDS-associated 
infection ultimately showed a long-term definitive 
response to Sb or any treatment.151 Similarly, in a separate 
analysis of the experience in Italy (which included the 35 
patients from Sicily), none of a total of 78 co-infected 
patients treated with Sb (n = 53) with liposomal ampho- 
tericin B (n = 1 l), or with various agents (n = 14) showed 
a definitive cure response. 155 
Iatrogenic Immunosuppression 
and Response to Treatment 
Iatrogenic immunosuppression also predictably predis- 
poses to reactivated (or perhaps newly acquired) visceral 
infection; however, this type of induced T cell deficiency 
may not as readily undermine treatment efficacy. At least 
33 solid organ transplant recipients rendered functionally 
T cell deficient by antirejection therapies have developed 
visceral leishmaniasis, often in a surprisingly delayed fash- 
ion, beyond the first year or even much longer after trans- 
plantation.1*“J56J57 Most of these cases have been reported 
from Mediterranean countries and presumably reflect reac- 
tivation of asymptomatic L. infanturn infection. In the 22 
patients who survived beyond the first week of hospital- 
ization and received either Sb (n = 18) or liposomal 
amphotericin B (n = 4) virtually all showed an initial cure 
response. Eight (seven of whom had received Sb) of these 
22 patients relapsed within 8 months after treatment; how- 
ever, the remaining 14 transplant recipients (64%) were 
reported relapse-free despite continued immunosuppres- 
sive therapy and no additional antileishmanial treatment 
with up to 3 to 4 years of follow-up.116,156~157 
Whereas the preceding results are limited and not 
readily comparable to the treatment experience in AIDS- 
related kala-azar, there may be higher apparent cure and 
perhaps lower relapse rates in infected transplant recip- 
ients. If real, such differences in responses to antileish- 
mania1 treatment probably reflect the severity of the T 
cell defect in CD4 cell-depleted AIDS patients compared 
to iatrogenically immunosuppressed individuals. Thus, 
the clinical (host defense) consequences of having a CD4 
cell count of less than 50 cells/mm3, for example, may 
be considerably more deleterious than the effects of con- 
ventional anti-transplant rejection therapy. The median 
CD4 cell count in patients with HIV-related kala-azar usu- 
ally is well under 50 cells/mm3 and may be as low as 20 
to 25 cells/mm3.35~154 
PROGRESS IN KALA-AZAR 
TREATMENT SINCE 1990 
In direct contrast to the state of limited therapeutic 
options in kala-azar in 1990, remarkable overall progress 
in treatment has been made since then (see Figure 1). 
Much of this progress has been generated via a success- 
ful combination of investigator-initiated and WHO-sup- 
ported clinical studies; more than 50 treatment studies 
have been carried out around the world in the past 10 
years. Table 1 summarizes these developments and high- 
lights new approaches that have included cytokine 
immunochemotherapy, testing new as well as “rediscov- 
ered” parenteral chemotherapeutic agents alone and in 
combination, short-course parenteral regimens, and oral 
therapy. 18-20,58-~,79,80,85,86,123,126-134,13~,139,145,158-183 
Flirtation with Cytokine Immunotherapy 
Interferon-y 
The initial hand-in-hand experimental and clinical devel- 
opment of IFN-?I as potential macrophage-activating, host 
defense-inducing treatment for intracellular infections in 
general and for leishmaniasis in particular, led to pilot tri- 
als in kala-azar in Brazil, Kenya, and India.57-61,14’,184 
Although the initial data in previously untreated patients 
were limited or uncontrolled,58@ combining daily IFN-y 
injections with Sb appeared to accelerate responses and 
enhance overall efficacy, synergistic effects predicted by 
experimental studies.53 In addition, retreatment with Sb 
plus IFN-y also induced long-lasting responses in about 
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New Approach or Development 
Table 1. Progress in Treatment of Kala-Azar, 1990-2000 
Number of Studies* Reference Number Current Status or Comment 
lmmunochemotherapy 
IFN-r + Sb 
GM-CSF + Sb 
Rediscovered agents 
Amphotericin B 
Reconfirmation of Sb efficacy+ 
Sudan 
New parenteral agents (not short-course regimens) 
Aminosidine 
AmBisome 
Combination chemotherapy 
Sb + aminosidine 
Short-course chemotherapy 
Amphotec 
Abelcet 
6 58-63 No further studies planned 
1 64 No further studies planned 
IO 79, 80, 123, 126-l 32 Wrdely used in India (Bihar State) 
2 133,134 Effective under arduous field conditions 
3 138,158,159 
2 145,160 
4 158. 161-163 
Additional trials planned in India 
U.S. FDA-approved for kala-azar in 1 997147 
No further trials planned 
2 164, 165 
4 166-l 69 
7 18-20, 170-l 73 
1 174 
1 176 
1 169 
1 173a 
No further trials planned 
Trial in progress in HIV-related kala-azar (Spain) 
5- to 1 O-day regimens active world-wide 
AmBisome 
Amphotericin B-fat emulsion* 
Liposomal amphotericin B (generic) 
Single-dose chemotherapy (India) 
Abelcet 
AmBisome 
Oral therapy 
Ketoconazole 
WR6026 
Fluconazole 
Atovaquone 2 fluconazole 
Miltefosine 
3 85, 86, 139 No further trials planned 
1 177 Trial in progress in Kenya 
1 178 No further trials planned 
1 179 No further trials planned 
4 180-l 83 First effective oral agent; phase Ill trial in adults and 
No further trials planned by WHO 
Additional trials planned in India 
5 mg/kg x 1 not sufficiently actrve (70% cure) 
5 mg/kg x 1 induced 91% cure; 7.5 mg/kg X 1 
now being tested 
phase l/II trial in children in progress in India 
*Excluding studies carried out specifically in patients co-infected with HIV; toutside of India; *also tested in a 25-day regimen.i75 
IFN-r = interferon-r, GM-CSF = granulocyte-macrophage colony-stimulating factor, AmBisome = liposomal amphotericin B, Amphotec = amphotericin B cholesterol 
dispkrsion, and Ab&cet = amphojericin B lipid complex: 
two-thirds of patients who were refractory to treatment 
with Sb alone.58x60 Results in small groups of European 
patientsG3 including several co-infected with Hn7,1s5 also 
pointed to IFN-y as a potentially useful adjunct. 
Nevertheless, in a subsequent randomized, controlled 
study in previously untreated subjects in India (Bihar),62 
combining IFN-y with Sb for 28 days increased the 
response but failed to induce a meaningful difference in 
long-term cure rates compared to treatment with Sb alone 
(49% vs. 36%, respectively). Although results in the third 
arm of this study (IFN=y plus Sb for 14 days, 42% appar- 
ent cure) showed that short-course combination treat- 
ment was as effective as either 28day regimen, responses 
in all three arms were unexpectedly Iow.~~ One likely 
explanation for low overall responses was the unantici- 
pated emergence of still higher-level Sb resistance in Bihar 
(e.g., a 64% failure rate in the Sb alone arm). Under such 
conditions, the majority of subjects receiving combination 
treatment may, in effect have been receiving IFN-y alone, 
treatment which is active in experimental infection but 
only modestly so in man.54l57 The combination of Sb plus 
IFN-?/ has not been formally retested. If such a study is 
undertaken again to re-examine the capacity of IFN-~ to 
accelerate the response to Sb or reduce the duration of 
treatment,“’ it should be carried out in a region where Sb 
resistance is low. 
Granulocyte-Macropbage 
Colony-StZmulatZng Factor 
In experimental infection, GM-CSF also induces macro- 
phage antileishmanial activity against L. donovani,’ and 
this effect is associated with both peripheral blood leuko 
cytosis and markedly increased entry of both monocytes 
and granulocytes into parasitized tissue. In GM-CSF-treated 
animals, inflammatory myeloid cells are drawn to and 
preferentially accumulate in a focal fashion at sites where 
granulomas are developing around infected resident 
macrophages.lo3 This latter effect, resulting in strikingly 
enhanced granuloma formation, is illustrated in Figure 3. 
Granulocyte-macrophage CSF was used in Sb-treated 
Brazilian children to take advantage of its well-recognized 
clinical capacity to mobilize neutrophils and monocytes 
to ameliorate the characteristic leukopenia of kala-azar 
and reduce susceptibility to secondary infections.64 
Results from this randomized pilot study suggested that 
the addition of GM-CSF to Sb treatment was well-toler- 
ated, did not exacerbate infection (an experimental con- 
cern derived from Leishmania major [but not L. 
donovani] modelslo3), and both accelerated recovery of 
the peripheral white blood cell count and reduced mostly 
minor secondary infections. However, there was no obvi- 
ous beneficial effect on the antileishmanial response to 
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Sb.64 No further experience with this Sb plus GM-CSF 
regimen has been reported in kala-azar. 
Parented Alternatives to Sb 
Aminosidine 
Recognized in the 1960s and again later as having exper- 
imental antileishmanial activity,ls6 the injectible amino- 
glycoside, aminosidine (identical to paromomycin), was 
first tested alone and in combination with Sb in visceral 
infection in Kenya.158 Subsequent studies were performed 
in India,161s162 the United Kingdom in imported cases,159 
and Sudan.163 The use of aminosidine plus Sb raised the 
possibility of two benelicial effects: offsetting the dimin- 
ishing efficacy of Sb and reducing the required duration 
of therapy.158J61-163 This latter effect was confirmed under 
arduous, partially controlled conditions in Sudan: 17 days 
of intramuscular treatments with Sb (20 mg/kg/d) plus 
aminosidine (15 mg/kg/d) proved as effective as 30 days 
of treatment with Sb alone.163 
More recently, and motivated by Sb unresponsiveness 
in India, the effect of aminosidine was examined in a con- 
trolled fashion by the WHO, in Biha~.*~* A 21-day course of 
aminosidine alone (16-20 mg&g/d) induced long-term cure 
in 93 to 97% of patients compared to 63% in those treated 
for 30 days with conventional Sb alone. These results led 
the investigators to consider aminosidine as a candidate for 
first-line therapy in Biha~.“~ The WHO has proposed that 
the cost of aminosidine per adult treatment course should 
not exceed U.S.$50187; an amount similar to the U.S.$50 to 
$60 cost of amphotericin B in India (Sb produced locally 
in India costs about U.S.$15 per adult course).72*169,188 Once 
supplies of aminosidine have been replenished by its new 
manufacturer, this agent will continue to be tested by the 
WHO as single-drug therapy in India. 
Rediscovery of Amphotericin B 
AS usefulness of pentamidine in Indian kala-azar faded 
and aminosidine was being more thoroughly studied, 
attention shifted to conventional amphotericin B deoxy- 
cholate, since there was essentially no other alternative 
in a region of Sb resistance. The most active antileish- 
mania1 agent experimentally,‘” amphotericin B proved 
nearly 100% effective when it first began to be employed 
in earnest in Sb-treatment failures.79~127-130 Although this 
agent was shown in the early 1990s to be feasible as ini- 
tial therapy in previously untreated subjects,Wx126 only rel- 
atively recently have investigators and clinicians in Bihar 
turned to amphotericin B as primary treatment. 
Current amphotericin B regimens in India are remark- 
ably active in both newly diagnosed and Sb-treated 
patients and regularly induce over 95% cure rates123~131~132; 
however, these regimens are typically prolonged and not 
necessarily well-tolerated. A lowdose protocol (0.5 mg/kg 
on alternate days over 28 days; total dose, 7 mg/kg) has 
produced conflicting results and appears to be seldom 
used.80~81~132~189 In contrast, a 99% cure rate has been 
reported for a full-dose, daily regimen (1 mg/kg/d for 20 
days; total dose, 20 mg/kg). 13’,13* However, this regimen 
has been in use at only one center,13* and because of con- 
cerns about toxicity, alternate-day schedules employing 
conventional doses probably are used most often. Exam- 
ples of these latter regimens include 15 infusions of 0.75 
or 1 .O mg/kg given every second day over a 30&y period 
(total dose, 1 l- 15 mg/kg). Recent experience in 229 chil- 
dren and adults from one unit in Bihar, where these alter- 
nate-day treatments are well-established, indicated that 
96% of patients completed therapy and that long-term 
cure responses were high (97-98%) in those who 
received total doses of either 11 or 15 mg/kg (Sundar S, 
Murray H. Unpublished data). 
Figure 3. Histologic effect of GM-CSF treatment in the liver of L. donovani-infected BALB/c mouse. A, Early, developing hepatic granuloma 
(arrows) in untreated control animal 3 weeks after infection. 13, Effects achieved by treating the same infected mice with GM-CSF during the pre- 
ceding 7 days, Treatment has induced marked influx of myelomonocytic cells, which have been recruited to a site of granuloma assembly and 
have encased the parasitized focus (Original magnification, X200). 
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Lipid-Associated Amphotericin B FormulatZons 
and Arrival of Short-Course Regimens 
Liposomal or lipid-formulated drugs are thought to be 
taken up preferentially by tissue macrophages, especially 
in high blood flow organs, such as the liver and spleen. 
Thus, with parasites lodged within sinusoidal macro- 
phages in these organs, visceral leishmaniasis was an ideal 
nonfungal intracellular infection in which to test the lipid 
preparations of amphotericin B. 
Amphotericin B cholesterol dispersion (Amphocil 
[now Amphotec], Sequus Pharmaceuticals, Inc., Menlo 
Park, CA) was the first of this new class of agents to be 
applied in kala-azar. Using Amphotec at 2 mg/kg per day 
in Brazil, 19 of 19 patients treated for 7 to 10 days (total 
dose, 14-20 mg/kg) and 9 of 10 treated for just 5 days 
(total dose, 10 mg/kg) experienced long-term cure.164,165 
Although additional studies with Amphotec have not 
been reported, more than a dozen trials using ampho- 
tericin B lipid complex (Abelcet, The Liposome Company, 
Princeton, NJ) or liposomal amphotericin B (AmBisome, 
NeXstar Pharmaceuticals, San Dimas, CA) have now been 
carried out around the world. - 1X 20,145,160,166-173 These stud- 
ies, which also have included successful testing of regi- 
mens as short as 5 to 10 days,18-20,170-1T3 and more recently 
singledose therapy,‘69,173a now incorporate experience in 
hundreds of adults and children. In 1997, the LJnited States 
Food and Drug Administration (FDA) approved the use 
of AmBisome for visceral infection.‘*’ 
One AmBisome trial in Brazil, in which 25 of 32 sub- 
jects were young children or teenagers, reported a cure 
rate of 78%, using 10 days of treatment and total doses of 
10 to 20 mg/kg. 172 With this exception, virtually all other 
studies using either AmBisome (throughout the develop- 
ing world) or Abelcet (thus far, only in India) have demon- 
strated 90 to 100% long-term cure responses provided 
sufficient total doses of drug were given (e.g., lo-15 
mg/kg for Abelcet 166-169; lo-20 mg/kg for AmBisome 
depending on the ~egion.‘~1s-20~145~160,1~o Total doses required 
to produce high-level responses are probably greatest in 
young children and appear to vary from region to region. l* 
Indian kala-azar seems most responsive to the lipid for- 
mulations of amphotericin B, including low-dose AmBi- 
some regimens, 18,1T1 which have induced greater than 90% 
cures with total doses of as little as 5-7.5 mg/kg.173,173a 
The 5 mg/kg total dose can be effectively administered as 
1 mg/kg/day for 5 days or as a single infusion of 5 
mg/kg.173a Both previously untreated patients and those 
who have failed prior Sb therapy respond equally well to 
these agents, and patients readily tolerate Abelcet and, 
especially, AmBisome. However, a direct comparison 
between the lipid preparations has not been (nor proba- 
bly ever will be) carried out, and in addition, none has 
been tested directly against conventional amphotericin B. 
The An&some regimen approved by the FDA for vis- 
ceral leishmaniasis in immunologically intact patients con- 
sists of seven infusions of 3 mg/kg given on days 1 to 5, 
14, and 21 (total dose, 21 mg/kg).‘*’ The estimated cost 
of drug alone in this regimen for a 25-kg patient is 
u.s.$2068 (25 kg X 21 mg/kg = 525 mg, representing 
eleven 50-mg vials at U.S.$lSS per 50-mg vial [average 
wholesale price]).‘% Thus, this drug and the FDA-approved 
treatment regimen is irrelevant to 90% or more of kala-azar 
patients who reside in rural areas of developing coun- 
tries. By way of comparison, average wholesale prices for 
50 or 100 mg of other amphotericin B-containing prepa- 
rations include: U.S. $17 for amphotericin B deoxycholate 
(50-mg vial, Fungizone, Bristol Myers-Squibb, Princeton, 
NJ) (u.s.$~ per 50-mg vial in India); U.S.$93 for Amphotec 
(50-mg vial); and U.S.$194 for Abelcet (lOO-mg vial).190 
In addition to being useful even under appalling out- 
patient field conditions, 170 the major clinical appeal of 
the lipid formulations of amphotericin B derives from 
high-level efficacy when given as short-course therapy 
This brief duration of treatment, especially 5- to lo-day 
schedules 18.20,164-168.170-173 and a recently tested single- 
dose protocol (173a), contrasts with 2& to 30-day Sb reg- 
imens and 20- to 30-day regimens using daily or 
alternate-day amphotericin B. Methods to reduce cost by 
using short-course (5-day), low-dose regimens (l-2 
mg/kg/d; total dose, 5-10 mg/kg’6’s169) can bring the 
expense of Abelcet, for example, into line with that of 
alternate-day amphotericin B if (1) cost savings from 
reduced length of hospital stay are taken into account 
and (2) the actual average wholesale ~cquz’sitz’on price is 
considered (Table 2),169 since average wholesale acquisi- 
tion prices are as much as 40 to 50% lower than listed 
average wholesale prices. Nevertheless, treatment with 
all three of the commercial lipid formulations of ampho- 
tericin B still remains difficult for most patients to afford. 
In addition, high drug cost is not readily offset by reduced 
hospital charges resulting from shorter admissions in 
areas such as India and Africa where expenses for hos- 
pitalization and clinic care are low. For example, although 
single-dose AmBisome therapy (5 mg/kg) cured 91% of 
Indian patients, ‘:* the overall cost of this shortest-course 
regimen still exceed that of conventional alternate-day 
amphotericin B given over 30 days, because of drug 
cost.173a However, in countries where hospital charges 
are substantial, high drug costs would probably be easily 
offset by savings resulting from the use of short-course, 
inpatient regimens. 
Although supported from a pharmacoeconomic per- 
spective, lowering the total dose of either Abelcet or 
AmBisome administered over a 5-day period, or attempts 
to reduce Abelcet costs further by using a single- or two- 
dose ultrashort course therapy results in variable 
increases in treatment failures, the inconvenience of and 
need for retreatment, and the possibility of encouraging 
parasite resistance. 167,16’),17j The latter problem, however, 
did not emerge in a series of four Abelcet trials carried 
out in India.1’fi-169 Among 32 of 220 patients who failed 
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Table 2. Cost Estimates for Selected Treatment Regimens for Kala-Azar in India* 
ABLC AB SAG+ Aminosidine AB-FAT 
Regimen 1 mg/kg/d 1 mglkg qod 20 mg/kg/d 16 mg/kg/d 2 mg/kg qod 
Days of treatment 5 30 30 21 10 
Hospital costs (U.S.$) 95 400 359 244 150 
Drug costs (U.S.$) 327 48 11 50 69 
Initial cost per patient (U.S.$) 422 448 370 294 219 
Treatment failurest (%) 10 2 10 7 7 
Final cost per patients 475 459# 423 331 256 
*Cost assumptions in U.S. dollars: (A) for a 25-kg patient hospitalized in endemic regions such as Bihar or Uttar Pradesh: (B) properly-preserved drug vials reused 
until empty: (C) hospital charges-(a) infusion supplies ($5 per infusion) except for SAG and aminosidine given by injection ($10 total for needles and syringes); (b) 
physician charge ($5): (c) laboratory charges ($10 per set of routine tests before and weekly until treatment end) plus three electrocardiograms for SAG ($9 total), and 
for each day during treatment: (d) hospital bed charge ($2), (e) food ($2), and (f) lost days at work for patient and attendant ($2.50 each); (D) drug charges-retail 
costs in India: SAG ($2.20/30-mL (100 mg/mL), amphotericin B ($6/50 mg), and fat emulsion ($13/250 ml); ABLC ($109/100 mg) cost represents an average 
acquisition cost not average wholesale price ($194 per 1 00-mg vial) and includes a 15% retail markup. 167,i74 Total aminosidine cost has been proposed by WHO as 
$50 per treatment course.‘87 +Pentavalent antimony (SAG) no longer is useful in Bihar because of resistance (see text); SAG data refer to use in other areas, such as 
Uttar Pradesh; *All treatment failures responded to an arbitrarily selected, short-course regimen: ABLC at 3 mg/kg/d for 5 days, a 100% effective regimen,‘67 with a 
per patient cost of $531 (drug, $436; hospital costs, $95); §[(lnitial cost per patient x 100 patients) + (cost of retreating treatment failures)]/lOO; “Final cost of 
alternate-day AB, using 15 infusions of 0.75 mg/kg rather than 1 mg/kg = $453. Final cost of a daily AB regimen, 1 mg/kg x 20 days,132 not widely used because of 
toxicity concerns = $391. AB = amphotericin B; ABLC = amphotericin B lipid complex; SAG = sodium antimony gluconate; AB-FAT = amphotericin B-fat emulsion: 
qod = every other day. 
to respond to or relapsed after receiving short-course, 
reduced-dose therapy (5-10 mg/kg, total), all 32 were 
retreated with and cured by short-courses of higher-dose 
Abelcet.‘@-lb9 
Ampboterictn B-Fat Endston 
as Cost-Eflecttve Treatment 
Although largely rendered irrelevant in the worldwide 
context of kala-azar treatment because of cost, the clear- 
cut clinical appeal and efficacy of short-course lipid 
amphotericin B regimens has fostered additional 
approaches. One approach has been local manufacture in 
an endemic region (India) of a liposomal amphotericin 
B preparation that currently is being tested and is 
expected to be marketed at a lower price.176 Another 
approach takes advantage of both the modest cost of 
standard amphotericin B and the efficacy of a lipid-asso- 
ciated drug by simply mixing amphotericin B deoxy- 
cholate with a commercially available fat emulsion. Such 
preparations have been used in other clinical settings and 
with apparent success in a limited number of Indian and 
European patients with kala-azar, including some co- 
infected with HIV 144~175~191 Recent results from a study of 
70 patients in Bihar, 23 of whom had failed prior Sb ther- 
apy, indicate that this approach is viable.“* Other than 
anticipated infusion-related fever and chills, treatment 
with amphotericin B diluted in 100 mL of a 20% lipid 
emulsion was well-tolerated, and 65 subjects (93%) expe- 
rienced long-term cure after having received five infusions 
of 2 mg/kg on alternate days (total dose, 10 mg/kg).“* 
The retail cost of amphotericin B produced in India 
is u.s.$~ per 50-mg vial and 100 mL of the lipid solu- 
tion used in the preceding study also cost U.S.$6.“* This 
$12 total cost per 50-mg dose is about 14-fold less than 
the cost of one 50-mg vial of AmBisome. In addition, 
treatment regimens for kala-azar can be analyzed by fac- 
toring in other practical costs, including those for hos- 
pital stay, laboratory monitoring, and retreating 
nonresponders. Table 2 illustrates such an analysis for an 
endemic region of India. (Although likely to be relevant 
to other endemic areas in the developing world, the 
information in Table 2 should be viewed as India-specific 
since such costs may vary considerably from country 
to country.) If one makes assumptions about various 
expenses (see Table 2 legend), the lo-day amphotericin 
B-fat emulsion regimen can be fairly estimated as about 
45% less expensive than, for example, conventional alter- 
nate-day amphotericin B treatment. Thus, although not 
yet tested directly against amphotericin B nor in a coun- 
try other than India, this lipid emulsion-based regimen 
appears to have clinical promise: it is suitable for use in 
the field and incorporates reduced drug and treatment 
costs, short hospital stay, satisfactory tolerability, and 
high-level efficacy. 17* 
Advantages and Disadvantages 
of Available Parenteral Regimens 
Despite well-recognized adverse reactions, including car- 
diotoxicity and pancreatitis,3~70~125 pentavalent Sb is con- 
sidered affordable and effective (except in Bihar, India); 
thus, it remains first-line therapy for kala-azar worldwide 
outside of Bihar.6 Even though few clinicians would con- 
sider Sb an ideal drug, Sb treatment (including its cost, 
duration of administration, and side-effects) continues to 
represent a standard against which one can measure 
other active parenteral agents. Because of Sb resistance, 
such measurement is obviously important in evaluating 
current and future alternative treatments in India, but at 
least for the present, is less germane to other endemic 
regions. Whether or not this latter conclusion will still 
be accurate in the next decade is not clear, since a recent 
report from Sudan, for instance, indicated a failure rate of 
18% in Sb-treated patients with kala-azar.12’ 
Selected examples of advantages and disadvantages 
among the available parenteral agents, distilled from the 
preceding discussion, include the following: 
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1. Amphotericin B and each of its lipid formulations 
are given by infusion, which requires fluids and intra- 
venous (IV) administration equipment; administering 
Sb and aminosidine by IV push or intramuscular 
injection requires only needles and syringes. 
2. AmBisome is active in short-course, 5- to lOday reg- 
imens and is associated with surprisingly few adverse 
reactions; however, its use (even as single-dose treat- 
ment) in endemic regions other than the Mediter- 
ranean is precluded by cost. 
3. Amphotericin B, Abelcet, and amphotericin B-fat 
emulsion routinely produce infusion-related fever and 
chills; however, these reactions diminish with subse- 
quent infusions. Other adverse reactions, including 
nephrotoxicity, may be less frequent with Abelcet or 
amphotericin B-fat emulsion compared to ampho- 
tericin B, in part because the former two can be 
given for considerably shorter periods. 
4. All currently available agents, including aminosidine, 
share the common disadvantage of requiring rela- 
tively frequent (at least once-weekly) laboratory mon- 
itoring. By definition, short-course regimens reduce 
the need for such monitoring. 
5. In Indian kala-azar, aminosidine is effective in a 21day 
course compared to 30 days for Sb or 20 to 30 days 
for daily or alternate-day amphotericin B; however, 
Abelcet and amphotericin B-fat emulsion are active 
when given for just 5 to 10 days. Amphotec also may 
be similarly active in short-course regimens but has 
not been sufficiently tested. 
6. Comparative cost estimates suggest that ampho- 
tericin B-fat emulsion treatment is most cost-effec- 
tive followed by aminosidine (assuming the 
projections of the WHO for the cost of aminosidine 
prove accurate) (see Table 2). Although the estimated 
final per patient cost of the selected treatment regi- 
men for Abelcet, amphotericin B, and Sb appear to 
be comparable, the brief duration of Abelcet therapy 
(5 consecutive days) makes this agent considerably 
more appealing. 
Outpatient Treatment 
Although hospital bed charges are typically low in devel- 
oping countries, this expense still figures in the cost analy- 
sis shown in Table 2. If treatment in India, for instance, was 
given in an outpatient clinic that charged little or nothing 
(unrealistic), an estimated $2 per day for each day of treat- 
ment could be subtracted from the cost of each regimen 
shown in Table 2 (e.g., a $60 saving for Sb or ampho- 
tericin B and a $42 saving for aminosidine treatment). 
Relatively little additional savings would be realized 
from outpatient treatment, for the short-course, lOday 
or less regimens shown in Table 2 (Abelcet, amphotericin 
B-fat emulsion). Nevertheless, it is still worth considering 
whether one or all five of the regimens included in Table 
2 could be successfully administered in an outpatient 
setting once patients who are not seriously ill have shown 
reasonable initial clinical improvement as well as drug 
tolerability. At the least, outpatient treatment would help 
to free hospital beds, which typically are in demand in 
these regions. Importantly, experience in Sudan, under 
the most difficult of epidemic conditions and with essen- 
tially no medical facilities, indicates that both pentavalent 
Sb and AmBisome can be given to seriously ill outpatients 
safely and with what appears to be high-level efficacy 13*~“” 
Whether the same is true for other agents or for adults and 
children in other regions that may not have some orga- 
nized framework of medical care or specified treatment 
protocols is unknown. 13*,170 Concerns about outpatient 
treatment for kala-azar include the dilemma of unappre- 
ciated or difficult-to-recognize drug toxicity, the absence 
of clinical guidelines to suggest when outpatient therapy 
is appropriate to begin, and the failure of partially treated 
patients to return for daily or alternate-day injections 
once they begin to recover their health. Despite such 
concerns, which are near-universal for outpatient man- 
agement of any infectious disease, this approach is logi- 
cal, should reduce costs, and deserves to be carefully 
evaluated, especially now that oral therapy in kala-azar is 
about to become a reality. 
Oral Therapy for Kida-Azar: 
Fact not Fancy in 2000 
Identification of an oral agent sufficiently active to induce 
long-term cure when used by itself has been a long 
sought-after therapeutic objective in kala-azar in all 
endemic regions. The list of oral antibiotics that have 
been tested at one time or another in visceral infection 
is extensive; more recently studied agents include keto- 
conazole,‘j9 fluconazole,17* atovaquone,179 and ~~6026, 
a primaquine analogue. lT7 However, the studies with these 
particular agents have shown only partial activity, yielded 
inconsistent results, or were too limited in scope to per- 
mit any firm conclusions to be drawn about clinical 
promise. In direct contrast, as this decade opens, it 
appears that the high-priority goal of identifying effec- 
tive oral therapy has in fact been achieved in the form of 
miltefosine. 
Mtltefosine 
Initially developed as an oral antineoplastic agent,192J9s 
hexadecylphosphocholine, a synthetic phospholipid 
derivative, was found more than 10 years ago to exert 
experimental antileishmanial activity.91-94 The initial phase 
I and II dose-ranging trial in kala-azar was successfully 
carried out in Bihar in 1997.‘*O In the past 2 years, three 
additional phase II studies have been rapidly completed 
in this same region, yielding consistent and striking ther- 
apeutic effects in both previously untreated and Sb-unre- 
sponsive patients.181-183 
The essential results of these four trials, which 
included 249 patients all older than 12 years (the effects 
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of mihefosine in young children are now being studied), 
can be summarized as follows: (1) overall, of 234 patients 
treated with total daily doses of 50 to 200 mg for 14 to 
42 days, 224 (96%) were long-term cures; (2) treatment 
with 50 mg twice-daily (100 mg/d) for 28 days cured 68 
of 70 subjects (97%); (3) this latter 100 mg/d regimen 
can be reduced to 21 days without a decrease in efficacy 
(treatment for just 14 days cured 89% of patients), and 
(4) whereas adverse gastrointestinal reactions to doses 
of 100 mg/d or higher are common, they are primarily 
mild and transient.1s0-183 For example, as many as one- 
half to two-thirds of miltefosine-treated subjects devel- 
oped vomiting or diarrhea most often during the first or 
second week of treatment; however, in most study 
patients given 100 mg/d, these reactions lasted for only 
1 or 2 days and resolved as therapy continued. Miltefos- 
ine treatment also can produce asymptomatic increases 
in liver transaminases and renal insufficiency; these reac- 
tions are reversible and, at 100 mg/d, are infrequent, typ- 
ically modest, and resolve as treatment proceeds.180-‘83 
Miltefosine is teratogenic in animals and should not be 
used in pregnant women. 
Additional miltefosine trials, nearing completion in 
India, include a phase I and II dose-escalation study in 
children (age, ~12 y) and a large, multicentered phase III 
study in adults and older children (age, 212). In the lat- 
ter trial, miltefosine is being administered for 4 weeks at 
100 mg/d (50 mg/d for those weighing ~25 kg) and a 
second arm is receiving conventional amphotericin B. 
Miltefosine has not yet been tested in kala-azar out- 
side of India nor in HIV-associated infection. In an exper- 
imental model of visceral leishmaniasis, miltefosine 
retains its in vivo leishmanicidal activity in mice devoid 
of both T cells and the macrophage-activating cytokine, 
IFN-)I.“’ Therefore, if patients with AIDS-related kala- 
azar tolerate this drug, there is no reason why it should 
not be active in this population. In such patients, mil- 
tefosine could be used both as initial therapy to induce 
remission and as life-long suppressive treatment, per- 
haps given just several times per week, to limit symp- 
tomatic recurrence. 19* 
TREATMENT OF KALA-AZAR IN THE FUTURE 
In the absence of effective vector control, vaccine to 
reduce the size of the susceptible population, and any rea- 
sonable method to control currently infected reservoirs 
(e.g., terrestrial mammals or man), the practical manage- 
ment of kala-azar will necessarily continue to revolve 
around optimizing current treatments; experimenting with 
new regimens, including drug combinations; and with 
luck, developing entirely new agents. In most endemic 
regions, of course, optimizing treatment is far from a sim- 
ple task and requires circumventing traditional obstacles 
to health care in the developing world and navigating 
within the restraining confmes of drug affordability, avail- 
ability, and actual applicability for use in the field. 
Nevertheless, the newly arrived, highly-active short- 
course parenteral and oral treatment regimens reviewed 
here, are relatively simple to administer, considerably 
more appealing to physician and patient alike (enhanc- 
ing compliance bilaterally), and associated with few late 
relapses. Thus, an additional clinical payoff from devel- 
oping these new regimens may be a reduction in the size 
of the currently infected reservoir and, therefore, theo- 
reticae, a decrease in new cases in regions where disease 
transmission is anthroponotic (e.g., India and probably 
to some extent other regions as well). 
The preceding line of reasoning also might be 
applied to, and the same type of potential benefit gained 
from the use of these more appealing treatment regimens 
in two other relevant groups of patients. First, one might 
consider preemptive oral therapy for those with sub- 
clinical visceral infection destined to evolve into fully 
established kala-azar.Ip5 However, before attempting to 
therapeutically abort such progression, a state presum- 
ably accompanied at some point by full-fledged commu- 
nicability, clinicians in the field would first need a suitable, 
noninvasive serologic method along the lines of testing 
fingerstick blood using an antigen-impregnated, 
immunochromatographic strip test.195 With high sensi- 
tivity and specificity, such a diagnostic test would not 
only have to initially identify subclinical infection, but 
then with utmost accuracy the high-risk subset of patients 
appropriate to treat. If proven feasible and effective, the 
benefits of this approach would theoretically include both 
fewer cases of overt disease and reduced transmission. 
Second, the new treatment regimens also should be 
tested in patients who develop post-kala-azar dermal leish- 
maniasis (PKDL), which occurs most commonly in Sudan, 
India, and East Africa. A poorly understood manifestation 
or sequela of kala-azar in which the skin harbors the par- 
asite 19’ PKDL develops in one-third to one-half of patients 
with Sudanese kala-azar, and skin involvement may be 
present either at the time kala-azar is first diagnosed or 
paradoxically within up to 6 months after visceral infec- 
tion has apparently been cured by Sb treatment.122,19s 
Sudanese PKDL, which often is self-limited in mild 
cases,199,200 appears to respond to Sb if treatment is 
required.‘“’ In contrast, in India, where PKDL complicates 
10 to 20% of all cases of visceral infection, skin involve- 
ment often does not appear until at least 1 or sometimes 
several years after successful treatment for kala-azar at a 
time when patients are systemically well and long free of 
clinically apparent infection elsewhere. 197*201 Indian PKDL 
is difficult to cure, and current suggested regimens are 
arduous: 120 days of daily Sb injections or alternate-day 
infusions of amphotericin B administered over GO to 90 
days. 201~202 Thus, if cosmetically important lesions are 
absent, it is hardly surprising that otherwise healthy indi- 
viduals with PKDL are not often interested in undergoing 
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Table 3. Optimal Drug Treatment for Kala-azar and Status of Selected New Therapeutic Regimens 
Characteristics of Optimal Agent or /deal Treatment Regimen* Aminosidinet ABLC+ AB-FAT Mi/tefosine+ 
Affordable Y N Y ? 
Safe, tolerated, and active (2 90% long-term cure) 
In adults Y Y Y Y 
In young children ? ? ? ? 
Suitable for use in the field Y Y Y Y 
Future drug supply satisfactory ? Y Y ? 
Oral administration N N N Y 
Short treatment duration (< 10 d) N Y Y N 
Once- or twice-daily dosing Y Y Y Y 
Little laboratory monitoring required N N N N 
Outpatient administration ? ? ? ? 
Active in all endemic regions (and against multiple visceral strains) ? ? ? ? 
Active against Sb-resistant strains Y Y Y Y 
Aborts progression of subclinical infection ? ? ? ? 
Reduces development of PKDL ? ? ? ? 
In HIV-related kala-azar 
Induces initial remission ? ? y144 ? 
Useful as suppressive therapy ? ? ? ? 
*Listed in order of priority from author’s perspective; treasons for selecting these new regimens for illustration: aminosidine (proposed low drug cost): ABLC 
(amphotericin B lipid complex [Abelcet]) (active as 5day regimen); AB-FAT (amphotericin B-fat emulsion) (low cost, active as IO-day regimen); and miltefosine (active 
as oral therapy). Although active in short-course regimens, AmBlsome is excluded here because of high cost. 
PKDL = post-kala-azar dermal leishmaniasis; Y = yes; N = no; ? = not known or not yet sufficiently tested. 
additional lengthy retreatment, especially with agents that 
are difficult to tolerate. 
Nevertheless, all patients with PKDL maintain some 
parasite load in the skin accessible to biting sandflies 
and, therefore, likely serve as reservoirs capable of per- 
petuating transmission and new infections in susceptible 
individuals. Testing patient-appealing approaches, such as 
one (or perhaps multiple) short courses of an ampho- 
tericin B lipid formulation (including drug diluted in fat 
emulsion) or certainly oral therapy (miltefosine) would 
be a natural next step in the management of PKDL in 
India and elsewhere. Although producing a good cos- 
metic result would be one goal, successfully reducing the 
size of this reservoir for anthroponotic transmission 
would be the ultimate objective of such treatment. A trial 
of miltefosine in PKDL is being planned in Bihar. 
Given the wealth of information generated in the past 
decade that has unraveled much of the complexity of the 
effective host defense response in kala-azar, it also is appro- 
priate to continue to develop the concept of manipulat- 
ing this immune response while also giving drug therapy 
For example, the notion of temporarily but rationally 
enhancing macrophage activation (IFN-Y),~‘J*~ raising the 
level of T cell reactivity,46.51,52J04 or amplifying the periph- 
eral blood or tissue leukocyte response (GM-CSF),64J03 all 
of which favor the parasitized host receiving drug treat- 
ment, remain particularly appealing goals. 
However, enthusiasm for additional clinical testing 
of adjunctive cytokine therapy in kala-azar is not high, at 
least currently Interleukin-12, another now clinically avail- 
able pro-host defense cytokine, may be an exception, 
since, in addition to readily inducing IFN-y, IL-12 stimu- 
lates a broader range of basic cellular immune mecha- 
nisms.*03 Recent in vivo experimental work also suggests 
that IL-12 can enhance the effect of Sb and induce 
antileishmanial activity in established visceral infec- 
tion.43*51*52*56~65~204 However, any future cytokine treatment 
in kala-azar patients will inevitably add some extra adverse 
reaction to any given regimen and, in the developing 
world, would presumably carry the difficult-to-surmount 
burden of high cost. Moreover and for the present, the 
arrival of both short-course and oral chemotherapeutic 
regimens in kala-azar has diminished clinical interest in 
further cytokine testing regardless of even strong exper- 
imental rationales. Nevertheless and as mentioned previ- 
ously, one can still ideally envision neutralization of the 
suppressive Th2 cell-associated response or short-term, 
adjunctive use of cytokines such as IL-12 or IFN-y or 
GM-CSF as part of a novel, multipronged therapeutic 
approach to kala-azar. Such an approach would be 
designed to sequentially redirect the host immune 
response, stimulate T cell activity, and better support or 
mobilize effector cells, thereby, enhancing the overall 
efficacy of chemotherapy 
Table 3 summarizes selected requirements for opti- 
mal drug treatment in kala-azar, indicates how well sev- 
eral of the new regimens currently compare with an ideal 
regimen, and highlights the directions that future trials 
with the four agents selected might take to address the 
listed unanswered questions. Whereas a number of the 
therapeutic requirements or priorities listed in Table 3 
as ideal would be the same for any worldwide infection 
that occurs primarily in developing countries, several are 
specific or particularly germane to kala-azar: high-level 
activity in areas of Sb resistance; safety and efficacy in 
young children as well as adults; effectiveness in multiple 
endemic regions and against multiple visceralizing strains; 
potential to abort progression of subclinical infection and 
to prevent the development of or successfully reduce 
communicability in established PKDL; and finally, the 
capacity to foster effective, life-long cell-mediated immu- 
nity to both prevent late relapses and resist reinfection. 
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Correction 
Amoxicillin for Fever and Sore Throat due to Non-exudative Pharyngotonsillitis: 
Beneficial or Harmful? 
In International Journal of Infectious Diseases, Volume 4, Number 2,2000, ‘Amoxicillin for Fever and Sore Throat 
due to Non-exudative Pharyngotonsillitis: Beneficial or Harmful?” page 73, some of the data in Table 3 was incorrectly 
placed. The corrected table appears below; please note these changes in your copy. 
Table 3. Duration of Fever and Sore Throat before and after Treatment, by Drug Group 
Variable 
Durations of Fever or Sore Throat (d) 
Mean 2 SD (Number of Cases) 
Amoxicillin Placebo 
95% C/ of Difference 
of the Duration P-Value 
Before treatment 
Fever 
Sore throat 
After treatment 
Fever 
Sore throat 
NA = not applicable. 
1.97 2 1.08 (584) 2.06 ‘-’ 1 .I 9 (584) NA 0.0670 
2.18 t 1.23 (591) 2.31 k 1.71 (588) NA 0.0870 
2.46 t 1.27 (431) 2.48 t 1.30 (436) -0.2, 0.1 0.7780 
3.01 2 1.84 (431) 3.04 2 1.86 (436) -0.3, 0.2 0.7990 
